A Randomised British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma
A Randomised British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma
复制标题
一项针对组织学侵袭性非霍奇金淋巴瘤患者的 CHOP 与每周多药治疗方案 (PACEBOM) 的随机英国国家淋巴瘤研究试验
DOI：
--
复制
发表时间：
2000
期刊：
影响因子：
--
通讯作者：
W. Gregory
中科院分区：
文献类型：
--
作者：
D. Linch;Paul D. Smith;B. Hancock;P. Hoskin;D. Cunningham;A. Newland;D. Milligan;P. A. Stevenson;J. Wood;K. Maclennan;B. Hudson;G. Hudson;W. Gregory
背景资料：在1987年至1991年期间，英国国家淋巴瘤调查将459例具有大细胞成分的非霍奇金淋巴瘤患者随机分配至CHOP或PACEBOM方案。患者和方法：459例符合条件的患者纳入本试验，根据工作公式，401例弥漫性大细胞淋巴瘤患者和58例弥漫性混合细胞淋巴瘤患者。226例患者随机接受CHOP治疗，233例接受PACEBOM治疗。试验的两组在所有潜在的预后因素方面平衡良好。结果：PACEBOM组完全缓解率为64%，CHOP组为57%（NS）。8年时，PACEBOM组的精算原因特异性生存率（CSS）为59%，而CHOP组为49%（P = 0.09）。PACEBOM组中年龄< 50岁的患者的CSS和总生存率均显著更好（P = 0.002），IV期疾病的CSS也显著改善（P = 0.02）。结论：本试验的成熟数据表明，含依托泊苷的多药每周方案上级CHOP方案。
Background: Between 1987 and 1991, the British National Lymphoma Investigation randomized 459 patients with non-Hodgkin's lymphoma with a large-cell component to either CHOP or the PACEBOM regimen. Patients and methods: Four hundred fifty-nine eligible patients were included in this trial, four hundred one with diffuse large-cell lymphoma and fifty-eight with diffuse mixed-cell lymphoma according to the Working Formulation. Two hundred twenty-six patients were randomized to receive CHOP and two hundred thirty-three to receive PACEBOM. The two arms of the trial were well balanced for all potential prognostic factors. Results: The complete remission rate with PACEBOM was 64% and with CHOP 57% (NS). At eight years, the actuarial cause specific survival (CSS) in the PACEBOM arm is 59% compared to 49% in the CHOP arm (P = 0.09). Patients < 50 years of age fared significantly better in the PACEBOM arm both for CSS and overall survival (P = 0.002) and the CSS was also significantly improved in stage IV disease (P = 0.02). Conclusions: The mature data from this trial suggest that an etoposide-containing multi-agent weekly regimen can be superior to CHOP.
影响因子：
158.5
作者：
FISHER, RI;GAYNOR, ER;MILLER, TP
通讯作者：
MILLER, TP